1. Academic Validation
  2. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer

Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer

  • Neoplasia. 2011 Jun;13(6):516-25. doi: 10.1593/neo.11122.
Geertje van der Horst 1 Christel van den Hoogen Jeroen T Buijs Henry Cheung Henny Bloys Rob C M Pelger Giocondo Lorenzon Bertrand Heckmann Jean Feyen Philippe Pujuguet Roland Blanque Philippe Clément-Lacroix Gabri van der Pluijm
Affiliations

Affiliation

  • 1 Department of Urology, Leiden University Medical Centre, Leiden, The Netherlands.
Abstract

Acquisition of an invasive phenotype by Cancer cells is a requirement for bone metastasis. Transformed epithelial cells can switch to a motile, mesenchymal phenotype by epithelial-mesenchymal transition (EMT). Recently, it has been shown that EMT is functionally linked to prostate Cancer Stem Cells, which are not only critically involved in prostate Cancer maintenance but also in bone metastasis. We showed that treatment with the non-peptide α(v)-integrin antagonist GLPG0187 dose-dependently increased the E-cadherin/vimentin ratio, rendering the cells a more epithelial, sessile phenotype. In addition, GLPG0187 dose-dependently diminished the size of the aldehyde dehydrogenase high subpopulation of prostate Cancer cells, suggesting that α(v)-integrin plays an important role in maintaining the prostate Cancer stem/progenitor pool. Our data show that GLPG0187 is a potent inhibitor of osteoclastic bone resorption and angiogenesis in vitro and in vivo. Real-time bioluminescent imaging in preclinical models of prostate Cancer demonstrated that blocking α(v)-integrins by GLPG0187 markedly reduced their metastatic tumor growth according to preventive and curative protocols. Bone tumor burden was significantly lower in the preventive protocol. In addition, the number of bone metastases/mouse was significantly inhibited. In the curative protocol, the progression of bone metastases and the formation of new bone metastases during the treatment period was significantly inhibited. In conclusion, we demonstrate that targeting of integrins by GLPG0187 can inhibit the de novo formation and progression of bone metastases in prostate Cancer by antitumor (including inhibition of EMT and the size of the prostate Cancer stem cell population), antiresorptive, and antiangiogenic mechanisms.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100506
    99.78%, Integrin Receptor Antagonist